Ming-Yu Lien1, Liang-Chih Liu2, Hwei-Chung Wang2, Ming-Hsin Yeh2, Chih-Jung Chen2, Su-Peng Yeh3, Li-Yuan Bai3, Yu-Min Liao1, Chen-Yuan Lin1, Ching-Yun Hsieh4, Ching-Chan Lin4, Long-Yuan Li5, Po-Han Lin6, Chang-Fang Chiu7. 1. Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. 2. Department of Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C. 3. Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Internal Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C. 4. Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan, R.O.C. 5. Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan, R.O.C. 6. Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Department of Medical Genetics, China Medical University Hospital, Taichung, Taiwan, R.O.C. Internal Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C. Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. pohanlin01@gmail.com cftl00@gmail.com. 7. Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, R.O.C. Internal Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C. pohanlin01@gmail.com cftl00@gmail.com.
Abstract
BACKGROUND/AIM: Pegylated liposomal doxorubicin (PLD) has been proven to be an effective antitumor drug for metastatic breast cancer, with less toxicity than conventional anthracycline. Our objective was to evaluate the efficacy and safety of PLD-based adjuvant chemotherapy compared to conventional chemotherapy for patients with stages I-III Triple-negative breast cancer (TNBC). PATIENTS AND METHODS: A total of 162 patients, histologically proven to have TNBC at stages I-III between 2003 and 2010, were enrolled to evaluate the impact of PLD- and non-PLD-based adjuvant chemotherapy by using the end-pint of overall survival (OS) and relapse-free survival (RFS). RESULTS: Forty-nine (30.2%) patients received PLD-based adjuvant chemotherapy and 113 (69.8%) a non-PLD regimen, including 84 (52%) patients receiving non-PLD anthracycline. The Kaplan-Meier calculation indicated no differences in RFS and OS between the PLD and non-PLD groups. Multivariate analysis adjusted for tumor size and lymph node status also revealed similar RFS (HR=0.86, 95% CI=0.43-1.73, p=0.678) and OS (HR=0.86, 95% CI=0.41-1.79, p=0.692) for PLD-based chemotherapy compared with non-PLD-based. Patients receiving PLD-based chemotherapy had a relatively lower incidence of grade 3-4 neutropenia (25% vs. 41.6%, respectively; p=0.054) and significantly higher incidence of hand-foot syndrome (16.3% vs. 4.4%, respectively; p=0.010). CONCLUSION: PLD-based adjuvant chemotherapy was as effective as conventional chemotherapy for patients with TNBC. PLD is an alternative for patients with TNBC when conventional anthracycline is inappropriate. Copyright
BACKGROUND/AIM: Pegylated liposomal doxorubicin (PLD) has been proven to be an effective antitumor drug for metastatic breast cancer, with less toxicity than conventional anthracycline. Our objective was to evaluate the efficacy and safety of PLD-based adjuvant chemotherapy compared to conventional chemotherapy for patients with stages I-III Triple-negative breast cancer (TNBC). PATIENTS AND METHODS: A total of 162 patients, histologically proven to have TNBC at stages I-III between 2003 and 2010, were enrolled to evaluate the impact of PLD- and non-PLD-based adjuvant chemotherapy by using the end-pint of overall survival (OS) and relapse-free survival (RFS). RESULTS: Forty-nine (30.2%) patients received PLD-based adjuvant chemotherapy and 113 (69.8%) a non-PLD regimen, including 84 (52%) patients receiving non-PLD anthracycline. The Kaplan-Meier calculation indicated no differences in RFS and OS between the PLD and non-PLD groups. Multivariate analysis adjusted for tumor size and lymph node status also revealed similar RFS (HR=0.86, 95% CI=0.43-1.73, p=0.678) and OS (HR=0.86, 95% CI=0.41-1.79, p=0.692) for PLD-based chemotherapy compared with non-PLD-based. Patients receiving PLD-based chemotherapy had a relatively lower incidence of grade 3-4 neutropenia (25% vs. 41.6%, respectively; p=0.054) and significantly higher incidence of hand-foot syndrome (16.3% vs. 4.4%, respectively; p=0.010). CONCLUSION: PLD-based adjuvant chemotherapy was as effective as conventional chemotherapy for patients with TNBC. PLD is an alternative for patients with TNBC when conventional anthracycline is inappropriate. Copyright